Compare CURI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURI | PRQR |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | Netherlands |
| Employees | 42 | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.4M | 166.5M |
| IPO Year | N/A | 2014 |
| Metric | CURI | PRQR |
|---|---|---|
| Price | $3.24 | $1.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $5.83 | ★ $7.25 |
| AVG Volume (30 Days) | ★ 579.6K | 566.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.91 | N/A |
| Revenue Next Year | $12.91 | $13.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $1.33 |
| 52 Week High | $6.06 | $3.10 |
| Indicator | CURI | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 47.38 |
| Support Level | $3.00 | $1.51 |
| Resistance Level | $3.56 | $1.58 |
| Average True Range (ATR) | 0.19 | 0.11 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 85.66 | 54.91 |
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.